Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

PFS Clinical Trial

Official title:
A Low Dose Decitabine Combined With Tirelizumab Prospective Phase II Clinical Study Comparing Tirelizumab in Patients With Advanced Esophageal Squamous Cell Carcinoma Who Did Not Progress With First-line Immunotherapy Combined With Chemotherapy

Status Not yet recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of low-dose decitabine combined with tirelizumab in the treatment of patients with advanced esophageal squamous cell carcinoma who did not progress in first-line immunotherapy combined with chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Squamous Cell
Esophageal Squamous Cell Carcinoma
PFS

Clinical Trial Details

NCT number	NCT05638984
Study type	Interventional
Source	Fudan University
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	January 1, 2023
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04425187` - Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC	Phase 2
Recruiting	`NCT05267366` - Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC	Phase 2
Recruiting	`NCT05267288` - Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02629718` - Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer	Phase 3
Recruiting	`NCT04520035` - Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell	Phase 2